Acrivon Therapeutics, Inc. reported a net loss of $18.2 million for the third quarter of 2025, a decrease from the $22.4 million loss recorded in the same period of 2024. For the nine months ending September 30, 2025, the company’s net loss was $58.9 million, slightly higher than the $57.7 million loss for the same period in 2024. The company has not generated any revenue to date and continues to operate at a loss, with an accumulated deficit of $255.9 million as of September 30, 2025. Total operating expenses for the third quarter were $19.7 million, down from $25.1 million in the prior year, primarily due to reduced research and development costs.
Research and development expenses for the third quarter of 2025 were $13.6 million, a decrease from $18.9 million in the same quarter of 2024. This reduction was attributed to fewer scheduled milestones and a strategic focus on endometrial cancer in the ACR-368 clinical trial. In contrast, expenses related to ACR-2316, another clinical asset, increased as the company initiated a clinical trial for this drug. General and administrative expenses remained stable at $6.0 million for both the third quarters of 2025 and 2024.
Acrivon continues to advance its clinical pipeline, with ACR-368 in a Phase 2 trial for endometrial cancer and ACR-2316 in Phase 1 studies for selected solid tumors. The company received Fast Track designation from the FDA for ACR-368 and has reported promising initial clinical data, including a 35% confirmed overall response rate in patients with endometrial cancer. The company is also leveraging its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to enhance drug development and patient selection for clinical trials.
As of September 30, 2025, Acrivon had cash, cash equivalents, and investments totaling $134.4 million, which the company believes will fund its operations into the second quarter of 2027. However, the company anticipates needing additional funding to support ongoing research and development activities, as well as potential commercialization efforts. Acrivon has indicated that it may pursue various financing options, including equity offerings and collaborations, to meet its future capital requirements. The company’s ability to raise funds may be influenced by market conditions and investor sentiment.
About Acrivon Therapeutics, Inc.
Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision oncology medicines using its proprietary AP3 proteomics platform. The company designs targeted cancer therapies and companion OncoSignature diagnostics to identify patients most likely to respond, focusing on tumors beyond genomics-based selection. Its pipeline includes selective inhibitors like ACR-368 and ACR-2316, aimed at treating solid tumors with high unmet needs through biomarker-driven patient stratification and rational drug combinations.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.